Defence is the Best Attack: Immuno-Oncology Breakthroughs

One of our most popular conferences, Defence is the Best Attack 2023 will be our fourth on this topic. Participants will learn about the most recent advances in immunotherapy, from the basic science to clinical studies, including the identification of novel targets. Topics to be covered immune checkpoints and innate immune response, microbioma, immune cell therapies, vaccines, and biomarkers of response to and mechanisms of resistance to immunotherapy. Alberto Montovani (Humanitas University), Tyler Jacks (MIT, USA), and Josep Tabnernero (VHIO, Spain) will give keynote speeches. 

Who should attend? 
The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad overview and detailed knowledge of the most recent advances in the field of immunotherapy.

Deadlines:  
Travel grant application deadline: 13 February 2023
Abstract submission deadline: 13 February 2023
Registration deadline: 13 March 2023 
 

Speakers: Andrea Ablasser (EPFL, Switzerland), Mustafa Diken (TRON/Biontech, Germany), Susan Galbraith (AstraZeneca, UK), Alena Gros (Vall d’Hebron Institute of Oncology, Spain), Sonia Guedan (Hospital Clínic de Barcelona, Spain), Jennifer Guerriero (Dana-Farber Cancer Institute, USA), Tyler Jacks (MIT, USA), Alberto Mantovani (Humanitas University, Italy), Ignacio Melero (Clínica Universidad de Navarra, Spain), Sergio Quezada (Cancer Research UK, UK), Yardena Samuels (Weizmann Institute of Science, Israel), Joan Seoane (Vall d'Hebron Institute of Oncology, Spain), Lillian Siu (University of Toronto, Canada), Marisol Soengas (Spanish National Cancer Research Centre, Spain), Josep Tabernero (Vall d'Hebron Institute of Oncology, Spain), Pablo Umana (Roche, Switzerland), and Keren Yizhak (Technion - Israel Institute of Technology, Israel). 

Keywords: oncology, molecular oncology, immuno-oncology, immune system interactions, novel therapeutic approaches to cancer, identification of novel targets, therapeutic interventions, biomarkers of immune response, mechanisms of intrinsic resistance, mechanisms of acquired resistance, chemotherapy resistance, immune checkpoints, innate immune response, microbioma, immune cell therapies, cancer vaccines, cancer research.